Puma and CANBridge cancel licensing deal for $20m
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
UBS Has Nine Biotech Buyout and Merger Candidates – 24/7 Wall St.
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Biotech punts near $300 million on Takeda discard
Opinion: 5 biotech stocks that could be the next big winners - MarketWatch
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma pounces on failed Takeda drug, snapping up cancer prospect
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Bio: Now Or Never. I Go With Never (NASDAQ:PBYI) | Seeking Alpha
